ArticleJournal of acquired immune deficiency syndromes (1999)2026
Impact of a Revised Ryan White Part A HIV Care Coordination Program on Viral Suppression and Durable Viral Suppression.
Article in Journal of acquired immune deficiency syndromes (1999), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of an HIV Care Coordination Program on All-cause, HIV-related, and Non-HIV-related Mortality in Younger and Older Adults With HIV in New York City, 2018-2022.Open forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn 2018, the New York City Health Department implemented a revised care coordination program (CCR) to facilitate delivery and strengthen the impact of an already effective intervention among people with HIV (PWH) struggling with viral suppression (VS). We examined CCR effects on 12-month VS and 36-month durable VS (DVS).
methodsUsing merged population-based HIV surveillance and Ryan White programmatic data, we identified PWH enrolled in the CCR between August 2018 and March 2021 and a contemporaneous group of CCR-eligible yet not enrolled PWH. We used inverse probability-weighted models to estimate CCR effects, stratified by baseline treatment status: lacking evidence of VS, newly diagnosed, inconsistently suppressed, and consistently suppressed.
resultsComparing the CCR with usual care, the adjusted relative risk [aRR] of VS was 1.91 (95% CI: 1.67 to 2.19) among those lacking evidence of VS, 1.30 (95% CI: 1.17 to 1.45) among those newly diagnosed, 1.14 (95% CI: 1.05 to 1.23) among those inconsistently suppressed, and 1.04 (95% CI: 0.94 to 1.16) among those consistently suppressed. Comparing the CCR with usual care, the aRR of DVS was 1.39 (95% CI: 1.09 to 1.77) among those lacking evidence of VS, 1.29 (95% CI: 0.98 to 1.71) among those newly diagnosed, 0.92 (95% CI: 0.79 to 1.09) among those inconsistently suppressed, and 1.07 (95% CI: 0.88 to 1.30) among those consistently suppressed.
conclusionsRelative to usual care, the CCR enhanced VS across most baseline treatment status groups and showed promise for DVS among PWH lacking evidence of VS or newly diagnosed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.